A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2019
Price : $35 *
At a glance
- Drugs VGX 3100 (Primary)
- Indications Anal intraepithelial neoplasia; Human papillomavirus infections; Squamous cell cancer
- Focus Therapeutic Use
- 16 Jul 2019 According to an Inovio Pharmaceuticals media release, interim data form the trial is expected in the second half of 2019.
- 08 Nov 2018 According to an Inovio Pharmaceuticals media release, interim efficacy data from this trial is expected in 2019.
- 21 Sep 2018 Planned End Date changed from 30 Jun 2021 to 21 Jan 2021.